A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

NCT06720038 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Vaccines

Interventions

BIOLOGICAL: 0.5 mL of the low dose VAX-31
BIOLOGICAL: 0.5 mL of the mid dose VAX-31
BIOLOGICAL: 0.5 mL of the high dose VAX-31
BIOLOGICAL: 0.5 mL dose of PCV20
BIOLOGICAL: 0.5 mL of the High-PFS dose VAX-31

Sponsor

Vaxcyte, Inc.